

## **California State Board of Pharmacy**

2720 Gateway Oaks Drive, Suite 100

Sacramento, CA 95833

Phone: (916) 518-3100 Fax: (916) 574-8618

www.pharmacy.ca.gov

Business, Consumer Services and Housing Agency Department of Consumer Affairs Gavin Newsom, Governor



# Notice of Meeting and Agenda Teleconference Licensing Committee Meeting

DATES & TIMES: April 5, 2023, 9:00 a.m.

NOTE: Pursuant to the provisions of Government Code section 11133, neither a public location nor teleconference locations are provided.

#### **INSTRUCTIONS FOR OBSERVATION:**

Livestream: <a href="https://thedcapage.blog/webcasts">https://thedcapage.blog/webcasts</a> Livestream will be available at 9:00 a.m. on April 5, 2023.

### FOR PUBLIC COMMENT, PLEASE LOG ON TO THIS WEBSITE:

FOR PUBLIC PARTICIPATION AND COMMENT FROM A REMOTE LOCATION, PLEASE LOG ON TO WEBEX: To access the WebEx event, attendees will need to click the following link and enter a first name, last name, email, and the event password listed below:

https://dca-meetings.webex.com/dca-

meetings/j.php?MTID=m97ffdbae4b5309a0f4cafbaa3afaa19f

## If joining using the link above

Webinar number: 2497 591 4399 Webinar password: CSBP04052023

## If joining by phone

+1-415-655-0001 US Toll

Access code: 249 759 14399

Passcode: 27270405

Members of the public participating via WebEx will be able to hear the meeting and provide public comment but may not be able to observe the meeting. The preferred audio connection is via phone bridge. The phone number and access code will be provided as part of your connection to the meeting. General instructions for using WebEx can be found at the end of the agenda.

Members of the public may but are not obligated to provide their names or personal information as a condition of observing or participating in the meeting. When signing into the WebEx platform, participants may be asked for their name and email address. Participants who choose not to provide their names will need to provide a unique identifier such as their initials or another alternative, so that the meeting moderator can identify individuals who wish to make public comment; participants who choose not to provide their email address may utilize a fictitious email address in the following sample format: <a href="mailto:XXXXX@mailinator.com">XXXXX@mailinator.com</a>.

#### FOR OBSERVATION ONLY:

Livestream: The Committee plans to livestream this meeting on the Department of Consumer Affairs' website at <a href="https://thedcapage.blog/webcasts">https://thedcapage.blog/webcasts</a>. Livestream will be available the earliest at 9:00 a.m. April 5, 2023. Using the Livestream link will allow only for observation with closed captioning. Livestream availability cannot, however, be

guaranteed due to resource limitations or technical difficulties. The meeting will not be cancelled if Livestream is unavailable. If you wish to participate, please plan to participate via the WebEx option listed above.

Important Notices to the Public: The Licensing Committee will hold a teleconference meeting via WebEx – access information is provided above. General instructions for using WebEx are attached to the agenda. The meeting is open to the public and is accessible to the physically disabled. A person who needs a disability-related accommodation or modification in order to participate in the meeting may make a request by contacting Debbie Damoth at (916) 518-3090, by emailing Debbie.Damoth@dca.ca.gov or sending a written request to the Board of Pharmacy, 2720 Gateway Oaks Drive, Suite 100, Sacramento CA 95833. Providing your request at least five business days before the meeting will help to ensure availability of the requested accommodation.

The time and order of agenda items are subject to change at the discretion of the Committee Chair. In the event a quorum of the Committee is unable to attend the meeting, or the Committee is unable to maintain a quorum once the meeting is called to order, the members present may, at the Chair's discretion, continue to discuss items from the agenda and make recommendations to the full board at a future meeting.

Government Code section 11125.7 provides the opportunity for the public to address each agenda item during discussion or consideration by the Committee or prior to the Committee taking any action on said item. Members of the public will be provided appropriate opportunities to comment on any issues before the Committee, but the Chair may, at his or her discretion, apportion available time among those who wish to speak. If public comment is not specifically requested, members of the public should feel free to request an opportunity to comment. Individuals may appear before the Committee to discuss items not on the agenda; however, the Committee can neither discuss nor take official action on these items at the time of the same meeting (Government Code sections 11125, 11125.7(a)).

# <u>Agenda</u>

Discussion and action may be taken on any item on the agenda.

April 5, 2023

Call to Order 9:00 a.m.

- I. <u>Call to Order, Establishment of Quorum, and General Announcements</u>
- II. <u>Public Comments on Items Not on the Agenda/Agenda Items for Future Meetings</u>
  Note: The Committee may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether

Page 2 of 3 California State Board of Pharmacy Licensing Committee Meeting Agenda April 5, 2023 to place the matter on the agenda of a future meeting. (Government Code sections 11125, 11125.7(a)).

- III. Approval of the January 24, 2023, Licensing Committee Meeting Minutes
- IV. <u>Discussion and Consideration of Provisions for Remote Processing</u>
- V. <u>Discussion and consideration of changes to the Board's Sample CPA related to MAT to Remove the Data 2000 waiver reference.</u>
- VI. <u>Discuss and Consideration of Possible Regulations to Implement Government Code</u>
  <u>Section 16.5 Related to Digital Signatures and Development of Policy Statement to</u>
  Facilitate Implementation of Digital Signatures of Applications and Other Notices
- VII. <u>Discussion and Consideration of Licensing Statistics</u>
- VIII. <u>Future Committee Meeting Dates</u>
- IX. Adjournment

Upon conclusion of business